RCKT241220C10000
- 0.00
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $40 From $44, Maintains Outperform Rating
Rocket Pharmaceuticals Shares Are Trading Lower After the Company Announced a $165 Million Upsized Public Offering of 13.2 Million Shares at $12.50 per Share.
Rocket Pharmaceuticals Intends To Offer And Sell $150M Of Shares Of Its Common Stock In Public Offering
Express News | Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
Rocket Pharmaceuticals on Track for Lowest Close Since September 2022 -- Data Talk
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Express News | Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
Sector Update: Health Care
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Rocket Pharmaceuticals to Resume Patient Enrollment in RP-L301 Gene Therapy Phase 2 Trial in 2025
Rocket Pharmaceuticals Has Not Initiated Enrollment in Phase 2 RP-L301 Study